Skip to main content

Press Releases and Ad-hoc Announcements

27 March 2024
PR: Heidelberg Pharma granted orphan drug designation by FDA for its proprietary ATAC candidate HDP-101
PDF
25 March 2024
PR: Heidelberg Pharma announces financial figures and reports on successful business performance in 2023
PDF
19 March 2024
PR: Heidelberg Pharma announces receipt of non-refundable upfront cash payment following the successful closing of its royalty purchase agreement with HealthCare Royalty
PDF
18 March 2024
PR: Heidelberg Pharma announces progress into Cohort 6 with its proprietary ATAC candidate HDP-101 in Phase I/IIa multiple myeloma study
PDF
06 March 2024
PR: Heidelberg Pharma to Present First Efficacy Data on HDP-101 and Data from Proprietary ADC Technology Platform at AACR Meeting 2024
PDF
04 March 2024
PR: Heidelberg Pharma Announces Royalty Financing Agreement with HealthCare Royalty for up to USD 115 million
PDF
04 March 2024
AH: Heidelberg Pharma Announces Royalty Financing Agreement with HealthCare Royalty for up to USD 115 million
PDF
29 November 2023
PR: Heidelberg Pharma Announces Changes to the Executive Management Board
PDF
29 November 2023
AH: Heidelberg Pharma Announces Changes to the Executive Management Board
PDF
15 November 2023
PR: Heidelberg Pharma Secures Patent for the Use of its ADC Technology Platform
PDF
02 November 2023
PR: Heidelberg Pharma Presents New Clinical Data from its Lead Candidate HDP-101 at the ASH Annual Meeting 2023
PDF
12 October 2023
PR: Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2023
PDF
19 September 2023
PR: Heidelberg Pharma Provides Update on Phase I/IIa Clinical Trial with Lead Candidate HDP-101
PDF
08 August 2023
PR: Heidelberg Pharma’s Partner Takeda Reached Development Milestone
PDF
13 July 2023
PR: Heidelberg Pharma Reports on First Half-Year 2023 and the Course of Business
PDF
29 June 2023
AH: Heidelberg Pharma Sells Minority Shareholding in Emergence Therapeutics
PDF
25 May 2023
PR: Heidelberg Pharma reports on the results of the Annual General Meeting 2023
PDF
05 May 2023
PR: Heidelberg Pharma appoints Chief Financial Officer
PDF
13 April 2023
PR: Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2023
PDF
04 April 2023
PR: Heidelberg Pharma Presents New Preclinical Data from its Proprietary ATAC Technology Platform at AACR Annual Meeting 2023
PDF
24 March 2023
PR: Heidelberg Pharma concludes very successful financial year 2022 and reports on course of business
PDF
16 December 2022
PR: Heidelberg Pharma Signs Research and Exclusive Option Agreement with Binghamton University on Immunostimulatory Technology Platform
PDF
14 December 2022
PR: Encouraging Clinical Data from Two Antibody Drug Conjugates Based on Heidelberg Pharma’s ATAC Technology Presented at the ASH Annual Meeting 2022
PDF
10 November 2022
PR: Heidelberg Pharma and Partner Magenta to Present Initial Clinical Data on their Antibody Drug Conjugates at the ASH Annual Meeting 2022
PDF
07 November 2022
PR: Heidelberg Pharma’s Partner Telix Reports Positive Data on the Pivotal ZIRCON Study
PDF
13 October 2022
PR: Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2022
PDF
04 October 2022
AH: Heidelberg Pharma AG Announces Adjustment of Guidance
PDF
09 September 2022
AH: Heidelberg Pharma Announces Conclusion of License Agreement with Partner Takeda To Develop an Antibody Targeted Amanitin Conjugate
PDF
30 August 2022
PR: Heidelberg Pharma AG Raises Approximately EUR 80 Million From Capital Measure
PDF
12 August 2022
PR: Heidelberg Pharma AG Launches Rights Issue of up to EUR 80 Million
PDF